Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
Details : New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and other cellular products.
Product Name : HS-110
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 25, 2022
Lead Product(s) : Erlotinib,Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Oncology Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The chemotherapeutic agent of claim is AQ4 & AQ4N. The bioactive agent is derived from the group of TNF-alpha, GM-CSF, IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40 Ligand.
Product Name : AQ4
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
February 26, 2021
Lead Product(s) : Erlotinib,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Oncology Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Quaratusugene Ozeplasmid,Erlotinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate
Details : United States Adopted Names (USAN) Council has approved the non-proprietary name quaratusugene ozeplasmid for GPX-001, formerly called Oncoprex™ immunogene therapy, the Company’s lead drug candidate for non-small cell lung cancer (NSCLC).
Product Name : Reqorsa
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 25, 2020
Lead Product(s) : Quaratusugene Ozeplasmid,Erlotinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed,Erlotinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genprex to Focus Its Clinical Efforts on Oncoprex with Osimertinib
Details : The company’s current Phase I/II clinical trial utilizes the combination of the EGFR inhibitor erlotinib and Oncoprex against NSCLC.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 02, 2020
Lead Product(s) : Undisclosed,Erlotinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable